The National Institute for Health and Care Excellence (NICE) has now recommended that Tecentriq (atezolizumab) from Roche may be used within...
Roche announced that Tecentriq SC (atezolizumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. It will be provided by the National Health Service (NHS) England.
Genentech, a member of the Roche Group announced that the FDA approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel...
The FDA has restricted use of Keytruda (pembrolizumab) from Merck Inc.and Tecentriq (atezolizumab) from Roche among patients with locally advanced...
Genentech announced data from the positive, pivotal Phase III OAK study of Tecentriq (atezolizumab) which showed Tecentriq helped people live...
Roche announced that results from the Phase III IMpower131 study showed Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel;...
Genentech/Roche announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq (atezolizumab) met its co-primary endpoints.
Genentech, a member of the Roche Group announced that the FDA approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide...
Genentech/Roche announced that the European Commission has approved Tecentriq (atezolizumab) plus chemotherapy (Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound);...
The European Commission has approved and granted marketing authorisation for Tecentriq (atezolizumab), from Roche, in combination with chemotherapy (carboplatin and...